Advanced Search
Submit Manuscript Volume 32, No 8, Aug 2022
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 32 Issue 8, August 2022: 777-780 |
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
Xiaoqiang Liu1,† , Yuhua Li2,† , Zhongfang Wang3,† , Shouchun Cao2,† , Weijin Huang2,† , Lin Yuan4,† , Yi-Jiao Huang5 , Yan Zheng1 , Jingjing Chen4 , Bo Ying6 , Zuoyun Xiang4 , Jin Shi4 , Jincun Zhao3,* , Zhen Huang4,* , Cheng-Feng Qin5,7,*
1Yunnan Province Centre for Disease Control and Prevention, Kunming, Yunnan, ChinaDear Editor,
To May 2022, the COVID-19 pandemic has claimed more than 6.28 million lives, with more than 524 million confirmed cases worldwide. The recent emergence of highly transmissible Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered another major surge in both confirmed cases and deaths.1 Ten COVID-19 vaccines have been approved by the World Health Organization (WHO) for emergency use, including the two mRNA vaccines, BNT162b2 and mRNA-1273, and two Chinese inactivated vaccines, CoronaVac and BBIBP-CorV. However, the rapid waning of vaccine-induced virus-neutralizing antibody titers and the continuous emergence of variants of concern (VOCs), including Alpha, Beta, Delta and Omicron, have created unprecedented challenges in the eradication of COVID-19 pandemic.2,3,4
https://doi.org/10.1038/s41422-022-00681-3